Tumor
Conditions
Interventions
Gold Standard:Pathological immunohistochemistry of PD-L1 expression
Index test:68Ga-DOTA-WL12 PET/CT non-invasive diagnostic ability for PD-L1 expression
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Voluntary trial, with the patient or their legal representative signing an informed consent form; (2) Patient selection: Select 100 patients who have been clinically diagnosed or diagnosed with malignant tumors in our hospital since December 1, 2024 (estimated based on the number of cancer cases in our hospital), with complete clinical and follow-up data; (3) The criteria for diagnosing all subjects as malignant tumor patients are based on medical history, clinical manifestations, other imaging examinations such as X-rays, CT, MRI, and 18F-FDG PET-CT, and follow-up for more than 6 months to confirm the diagnosis
Exclusion criteria
Exclusion criteria: (1) Individuals with a history of allergies to similar drugs (drugs with similar chemical or biological components to PD-L1), allergic constitution, or current allergic diseases; (2) Individuals who are currently undergoing clinical trials of other drugs or have participated in clinical trials of any drugs (excluding vitamins and minerals); (3) There are other clinical problems that are difficult to control (such as HIV, hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other system diseases); (4) Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test); (5) Patients whose physical condition is not suitable for radiation examination; (6) Researchers believe that exclusion is necessary.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| standardized uptake value;Accuracy ;Sensitivity;Specificity;Positive predicative value;negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| PD-L1 expression tumor volume;total lesion PD-L1 expression; | — |
Countries
China
Contacts
Public ContactCheng Zhuzhong
Sichuan Cancer hospital
Outcome results
None listed